Open Access
J Oral Med Oral Surg
Volume 27, Number 1, 2021
Article Number 16
Number of page(s) 8
Published online 11 December 2020
  1. Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 2018;28:913–921. [CrossRef] [PubMed] [Google Scholar]
  2. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 2013;15:335. [CrossRef] [PubMed] [Google Scholar]
  3. Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol 2019;29:1–9. [CrossRef] [PubMed] [Google Scholar]
  4. Poten PC. Morve chronique de forme anormal. Bull et Mem Hop Paris. 1875;12:314–318. [Google Scholar]
  5. Unverricht H. Dermatomyositis acuta. Dtsch Med Wochenschr 1891;17:41–44. [CrossRef] [Google Scholar]
  6. Tanaka TI, Geist SM. Dermatomyositis: a contemporary review for oral health care providers. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:e1–8. [CrossRef] [PubMed] [Google Scholar]
  7. Heath KR, Fazel N. Oral Signs of Connective Tissue Disease. In Oral Signs of Systemic Disease 2019 (pp. 91–112). Cham: Springer. [CrossRef] [Google Scholar]
  8. Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol 2018;36:450–458. [CrossRef] [PubMed] [Google Scholar]
  9. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664–678. [CrossRef] [PubMed] [Google Scholar]
  10. Kim JS, Bashir MM, Werth VP. Gottron's papules exhibit dermal accumulation of CD44 variant 7 (CD44v7) and its binding partner osteopontin: a unique molecular signature. J Invest Dermatol 2012;132:1825–1832. [CrossRef] [PubMed] [Google Scholar]
  11. Nabatian AS, Bashir MM, Wysocka M, Sharma M, Werth VP. Tumor necrosis factor alpha release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther 2012;14:R1. [CrossRef] [PubMed] [Google Scholar]
  12. Hu HC, Cho HY, Chiu YH. Dermatomyositis induced by filler rhinoplasty using liquid silicone. JAMA Otolaryngol 2020;146:205–206. [Google Scholar]
  13. Maan MA, Akhtar SJ, Haque H. Dermatomyositis. J Pakistan Assoc Dermatol 2016;18:33–43. [Google Scholar]
  14. Mainetti C, Terziroli Beretta-Piccoli B, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol 2017;53:337–356. [CrossRef] [PubMed] [Google Scholar]
  15. Adi AH, Alturkmani H, Spock T, Williams Yohannes P, Wargo S, Szabo E, et al. Dermatomyositis paraneoplastic syndrome before symptomatic tonsillar squamous cell carcinoma: a case report. Head Neck 2015;37:E1–E3. [CrossRef] [PubMed] [Google Scholar]
  16. Ruparelia P, Verma O, Shah V, Shah K. Juvenile Dermatomyositis − a case report with review on oral manifestations and oral health considerations. Int J Orofacial Myol 2018;44:52–61. [Google Scholar]
  17. Dourado MR, da Silva Filho TJ, Salo T. Oral signs in juvenile dermatomyositis. J Oral Diag 2017;2:1–5. [CrossRef] [Google Scholar]
  18. Bernet LL, Lewis MA, Rieger KE, Casciola-Rosen L, Fiorentino DF. Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1γ (p155) antibodies. JAMA Dermatol. 2016;152:1049–1051. [CrossRef] [PubMed] [Google Scholar]
  19. Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep 2010;12:192–197. [CrossRef] [PubMed] [Google Scholar]
  20. Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 2020;21:339–353. [CrossRef] [PubMed] [Google Scholar]
  21. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthr Rheumatol 2017;69:2271–2282. [CrossRef] [Google Scholar]
  22. Pinal-Fernandez I, Mammen AL. Dermatomyositis etiopathogenesis: a rebel soldier in the muscle. Curr Opin Rheumatol. 2018;30:623–629. [CrossRef] [PubMed] [Google Scholar]
  23. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6–13. [CrossRef] [PubMed] [Google Scholar]
  24. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14:275–285. [CrossRef] [PubMed] [Google Scholar]
  25. Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile .dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60:1825–1830. [CrossRef] [PubMed] [Google Scholar]
  26. Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology 2019. [Google Scholar]
  27. Mayu S, Isojima S, Miura Y, Nishimi S, Hatano M, Tokunaga T, et al. Polymyositis-dermatomyositis and interstitial lung disease in pregnant woman successfully treated with cyclosporine and tapered steroid therapy. Case Rep Rheumatol. 2019. [Google Scholar]
  28. Nawata T, Kubo M, Okuda S, Omoto M, Yujiri T, Kanda T, et al. Successful treatment with intravenous cyclophosphamide for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis associated with myelodysplastic syndrome. Scand J Rheumatol. 2017;46:496–498. [CrossRef] [PubMed] [Google Scholar]
  29. Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clin Exp Dermatol. 2018;43:906–912. [CrossRef] [PubMed] [Google Scholar]
  30. Marie I, Menard J-F, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62:1748–1755. [CrossRef] [PubMed] [Google Scholar]
  31. Chen KL, Zeidi M, Werth VP. Recent advances in pharmacological treatments of adult dermatomyositis. Curr Rheumatol Rep 2019;21:53. [CrossRef] [PubMed] [Google Scholar]
  32. Rodziewicz M, Kiely P. The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease. Rheumatology 2018;57:1866–1867. [PubMed] [Google Scholar]
  33. Ioannou E. Thu0718-hpr overview of the most effective physiotherapy management methods in pediatric rheumatology. Ann Rheumatic Dis 2019;78:655–657. [Google Scholar]
  34. Goyal NA, Mozaffar T. Novel therapeutic options in treatment of idiopathic inflammatory myopathies. Curr Treatment Options Neurol. 2018;20:37. [CrossRef] [Google Scholar]
  35. Pearson DR, Werth VP. AB005. Unilateral vocal cord paresis in classic dermatomyositis. Ann Transl Med. 2019;7:AB005. [CrossRef] [Google Scholar]
  36. Traineau H, Aggarwal R, Monfort JB, Senet P, Oddis CV, Chizzolini C, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature. J Am Acad Dermatol. 2020;82:317–325. [CrossRef] [PubMed] [Google Scholar]
  37. Isak V, Jorizzo JL. Recent developments on treatment strategies and the prognosis of dermatomyositis: a review. J Dermatolog Treatm. 2018;29:450–459. [CrossRef] [Google Scholar]
  38. Cassius C, Le Buanec H, Bouaziz JD, Amode R. Biomarkers in adult dermatomyositis: tools to help the diagnosis and predict the clinical outcome. J Immunol Res. 2019;2019. [Google Scholar]
  39. Healy CM, Tobin AM, Kirby B, Flint SR. Oral lesions as an initial manifestation of dermatomyositis with occult malignancy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101:184–187. [CrossRef] [PubMed] [Google Scholar]
  40. Gonçalves LM, Bezerra-Júnior JR, Gordón-Núñez MA, Libério SA, de Fátima V, Pereira A, et al. Oral manifestations as important symptoms for juvenile dermatomyositis early diagnosis: a case report. Pediatr Dent 2011;21:77–80. [CrossRef] [Google Scholar]
  41. Escobar A, Aitken-Saavedra JP. Xerostomia: an update of causes and treatments. In Salivary Glands-New Approaches in Diagnostics and Treatment 2018 Nov 5. IntechOpen. [Google Scholar]
  42. Adamczak MI, Martinsen OG, Smistad G, Hiorth M. Polymer coated mucoadhesive liposomes intended for the management of xerostomia. Int J Pharmaceut. 2017;527:72–78. [CrossRef] [Google Scholar]
  43. Gurkar H, Venkatesh OY, Somashekar JM, Gowda MH, Dwivedi M, Ningthoujam I. Prosthodontic management of xerostomic patient: a technical modification. Case Rep Dent 2016;2016. [Google Scholar]
  44. Geist SM, Tanaka TI. Oral lichen planus in a dermatomyositis patient that resolved after intravenous immunoglobulin therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118:e111–e114. [CrossRef] [PubMed] [Google Scholar]
  45. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71:710–713. [CrossRef] [PubMed] [Google Scholar]
  46. Bassim CW, Gibson G, Ward T, Paphides BM, Denucci DJ. Modification of the risk of mortality from pneumonia with oral hygiene care. J Am Geriatr Soc 2008;56:1601–1607. [CrossRef] [PubMed] [Google Scholar]
  47. Rowen RJ. Remission of aggressive autoimmune disease (dermatomyositis) with removal of infective jaw pathology and ozone therapy: review and case report. Autoimmun Highlights 2018;9:1–7. [CrossRef] [Google Scholar]
  48. Sarifakioglu N, Terzioglu A, Ates L, Bingül F, Aslan G. Bilateral symmetric mandibular calcified nodules related to juvenile dermatomyositis. J Oral Maxillof Surg 2003;61:527. [CrossRef] [Google Scholar]
  49. Greer RO, Galbraith CT, Scheidt MJ, Aubry P, Glasgow MJ. Dermatomyositis with calcifications of the periodontal ligament: a rare oral finding. Dermatol Case Rep 2016;1:110. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.